

October 24, 2022

Kidswell Bio Corporation

Code: 4584 (TSE Mothers)

Masaharu Tani, President & CEO

Announcement of a patent application on cell therapy for cerebral palsy utilizing SHED with Tokai National Higher Education and Research System (Extracted from Japanese version)

Tokyo, October 24, 2022 – Kidswell Bio Corporation (KWB) is delighted to announce that the joint patent application agreement was executed with Nagoya University (Tokai National Higher Education and Research System is established in April 2020 including Nagoya University and Gifu University) and the patent on the cell therapy for cerebral palsy utilizing SHED (stem cells from human exfoliated deciduous teeth) was applied through the collaborative research with KWB and Nagoya University.

Recognizing a various range of business development potential in this cell therapy, KWB will proceed with research and development such as drug efficacy study and aim for licensing out to pharmaceutical companies early while securing intellectual property.

The financial impact on the business results for the fiscal year ending March 2023 is expected to be minimal.

About Kidswell Bio Corporation (KWB)

Kidswell Bio Corporation will challenge pediatric disease as a new field, in addition to intractable and rare diseases on which KWB has also been focusing for R&D. We would like to contribute to children who have hopes and dreams for their bright future. Furthermore, with our biotech expertise and children's potential vital force such as SHED, stem cell from exfoliated deciduous teeth, we envision creating new pharmaceuticals and therapeutics for all people under "Kids Well, All Well."

Contact:

Kidswell Bio Corporation

Tel: +81-3-6222-9547 Mail: info@kidswellbio.com